Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...

The constant threat of recurrence feels like the proverbial sword of Damocles — always present, always waiting. If my cancer does return, the now-inert metal seeds scattered through my prostate and ...

A mainstay of prostate cancer treatment at all stages is a type of hormone therapy called androgen deprivation therapy (ADT).

With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a ...

Berlin: Bayer has received marketing authorization from the European Commission in the European Union (EU) for Nubeqa ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...

European Union approves Bayer’s Nubeq for patients with advanced prostate cancer: Berlin Tuesday, July 22, 2025, 11:00 Hrs [IST] The European Commission has granted marketing au ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...

In patients with biochemical recurrence after prostate cancer surgery, the optimal duration of hormone therapy after salvage radiation therapy has been debated.

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...